Dataset Information

Rhamnosidase activity of selected probiotics and their ability to hydrolyse flavonoid rhamnoglucosides.

ABSTRACT: Bioavailability of flavonoids is low, especially when occurring as rhamnoglucosides. Thus, the hydrolysis of rutin, hesperidin, naringin and a mixture of narcissin and rutin (from Cyrtosperma johnstonii) by 14 selected probiotics was tested. All strains showed rhamnosidase activity as shown using 4-nitrophenyl ?-L-rhamnopyranoside as a substrate. Hesperidin was hydrolysed by 8-27% after 4 and up to 80% after 10 days and narcissin to 14-56% after 4 and 25-97% after 10 days. Rutin was hardly hydrolysed with a conversion rate ranging from 0 to 5% after 10 days. In the presence of narcissin, the hydrolysis of rutin was increased indicating that narcissin acts as an inducer. The rhamnosidase activity as well as the ability to hydrolyse flavonoid rhamnoglucosides was highly strain specific. Naringin was not hydrolysed by rhamnosidase from probiotics, not even by the purified recombinant enzyme, only by fungal rhamnosidase. In conclusion, rhamnosidases from the tested probiotics are substrate specific cleaving hesperidin, narcissin and to a small extent rutin, but not naringin.

SUBMITTER: Mueller M

PROVIDER: S-EPMC5773629 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Rhamnosidase activity of selected probiotics and their ability to hydrolyse flavonoid rhamnoglucosides.

Mueller Monika M Zartl Barbara B Schleritzko Agnes A Stenzl Margit M Viernstein Helmut H Unger Frank M FM

Bioprocess and biosystems engineering 20171110 2

Bioavailability of flavonoids is low, especially when occurring as rhamnoglucosides. Thus, the hydrolysis of rutin, hesperidin, naringin and a mixture of narcissin and rutin (from Cyrtosperma johnstonii) by 14 selected probiotics was tested. All strains showed rhamnosidase activity as shown using 4-nitrophenyl α-L-rhamnopyranoside as a substrate. Hesperidin was hydrolysed by 8-27% after 4 and up to 80% after 10 days and narcissin to 14-56% after 4 and 25-97% after 10 days. Rutin was hardly hydro ...[more]

PMID: 29124335

Similar Datasets

Project description:Introduction: The flavonoid myricetin has been shown to induce cell cycle arrest and mitochondrial-dependent apoptosis in preclinical cancer models. We hypothesised that myricetin-derived flavonoids with redox properties and improved physicochemical attributes that enhance cell uptake and mitochondrial targeting might have increased potential as antitumour agents, since mitochondria are the main site of production of reactive oxygen species (ROS) and redox status is known to regulate the development and advancement of certain cancers. In this study we assessed a small library of novel flavonoids, then focussed on the lead compound, second-generation analogue OncamexTM, its mechanism of action and structure-activity relationships as an anti-proliferative agent. Methods: With this aim, we studied the effect of OncamexTM in a panel of 7 breast cancer cell lines using proliferation, cytotoxicity and apoptosis assays. The redox properties and mitochondrial delivery of the drug were studied using cyclic voltammetry and fluorescence microscopy, respectively. The mechanism of action was further studied using western blotting, gene expression analysis and immunohistochemistry (IHC) of treated xenograft tissue from in vivo mice models. Results: Sulforhodamine B (SRB) proliferation assays demonstrated strong, anti-proliferative properties of OncamexTM, with IC50 values in the low micromolar range. Treatment for 8 h exerted concentration-dependent reduction in cell viability and induction of cytotoxicity and apoptosis, with increased caspase activation. Microarray analysis suggested that OncamexTM regulates changes in cell cycle and apoptosis at gene expression level. Fluorescence microscopy was used to investigate mitochondrial targeting and ROS regulation in treated cells. OncamexTM was found to induce production of superoxide at concentrations which exerted anti-proliferative effects. Initial in vivo studies in mice implanted with a MDA-MB-231 breast cancer xenograft showed that OncamexTM inhibited tumour growth, reducing tissue viability and Ki-67 proliferation, with no overall systemic toxicity. Conclusions: OncamexTM is a novel flavonoid capable of specific delivery to the mitochondria and induction of ROS production. We have shown its antitumor activity in preclinical models of breast cancer, both in vitro and in initial in vivo models, where tumour growth was arrested without inducing toxicity, support the potential of this novel drug for its continued development as an anticancer agent. Total RNA was obtained from 5 breast cancer cell lines subjected to 6 hours of 10µM OncamexTM and matched untreated controls (1% DMSO)

Dataset Information

Rhamnosidase activity of selected probiotics and their ability to hydrolyse flavonoid rhamnoglucosides.

Publications

Rhamnosidase activity of selected probiotics and their ability to hydrolyse flavonoid rhamnoglucosides.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets